(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(-1.31%) $82.75
(6.34%) $2.05
(0.03%) $2 348.00
(-0.21%) $27.48
(3.91%) $958.15
(-0.22%) $0.933
(-0.34%) $10.99
(-0.55%) $0.796
(1.66%) $93.40
0.00% HKD 0.560
Live Chart Being Loaded With Signals
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in the People's Republic of China...
Stats | |
---|---|
Tagesvolumen | 16.35M |
Durchschnittsvolumen | 7.60M |
Marktkapitalisierung | 5.20B |
EPS | HKD0 ( 2024-03-27 ) |
Last Dividend | HKD0.0370 ( 2023-06-06 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -56.00 |
ATR14 | HKD0.00100 (0.18%) |
Volumen Korrelation
Sihuan Pharmaceutical Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Sihuan Pharmaceutical Korrelation - Währung/Rohstoff
Sihuan Pharmaceutical Finanzdaten
Annual | 2023 |
Umsatz: | HKD1.86B |
Bruttogewinn: | HKD1.30B (69.64 %) |
EPS: | HKD-0.00580 |
FY | 2023 |
Umsatz: | HKD1.86B |
Bruttogewinn: | HKD1.30B (69.64 %) |
EPS: | HKD-0.00580 |
FY | 2022 |
Umsatz: | HKD2.18B |
Bruttogewinn: | HKD1.49B (68.20 %) |
EPS: | HKD-0.210 |
FY | 2021 |
Umsatz: | HKD3.29B |
Bruttogewinn: | HKD2.45B (74.39 %) |
EPS: | HKD0.0440 |
Financial Reports:
No articles found.
Sihuan Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0.0360 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.0370 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0390 | 2011-09-21 |
Last Dividend | HKD0.0370 | 2023-06-06 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 23 | -- |
Total Paid Out | HKD0.764 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.03 | -- |
Div. Sustainability Score | 3.27 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0.991 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
3866.HK | Ex Dividend Junior | 2023-06-02 | Annually | 0 | 0.00% | |
1731.HK | Ex Dividend Junior | 2023-06-23 | Sporadic | 0 | 0.00% | |
0771.HK | Ex Dividend Junior | 2023-05-31 | Sporadic | 0 | 0.00% | |
2327.HK | Ex Dividend Junior | 2023-08-03 | Sporadic | 0 | 0.00% | |
1290.HK | Ex Dividend Junior | 2023-06-14 | Sporadic | 0 | 0.00% | |
0363.HK | Ex Dividend Knight | 2023-06-01 | Annually | 0 | 0.00% | |
6117.HK | Ex Dividend Junior | 2023-05-22 | Sporadic | 0 | 0.00% | |
1857.HK | Ex Dividend Junior | 2023-08-23 | Semi-Annually | 0 | 0.00% | |
0881.HK | Ex Dividend Junior | 2023-06-23 | Annually | 0 | 0.00% | |
0026.HK | Ex Dividend Junior | 2023-10-03 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0290 | 1.500 | -0.581 | -0.871 | [0 - 0.5] |
returnOnAssetsTTM | -0.00468 | 1.200 | -0.156 | -0.187 | [0 - 0.3] |
returnOnEquityTTM | -0.0122 | 1.500 | -1.247 | -1.870 | [0.1 - 1] |
payoutRatioTTM | -5.53 | -1.000 | -10.00 | 10.00 | [0 - 1] |
currentRatioTTM | 1.511 | 0.800 | 7.45 | 5.96 | [1 - 3] |
quickRatioTTM | 1.160 | 0.800 | 7.88 | 6.30 | [0.8 - 2.5] |
cashRatioTTM | 0.920 | 1.500 | 6.00 | 9.00 | [0.2 - 2] |
debtRatioTTM | 0.106 | -1.500 | 8.23 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.00318 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -0.00510 | 2.00 | -0.00255 | -0.00510 | [0 - 20] |
debtEquityRatioTTM | 0.277 | -1.500 | 8.89 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.696 | 1.000 | 1.727 | 1.727 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.0736 | 1.000 | -3.47 | -3.47 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.0231 | 1.000 | -0.983 | -0.983 | [0.2 - 2] |
assetTurnoverTTM | 0.161 | 0.800 | -2.26 | -1.806 | [0.5 - 2] |
Total Score | 3.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -85.44 | 1.000 | -8.73 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0122 | 2.50 | -0.802 | -1.870 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.00510 | 2.00 | -0.00170 | -0.00510 | [0 - 30] |
dividendYielPercentageTTM | 7.14 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.00318 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | -5.53 | 1.500 | -10.00 | 10.00 | [0 - 1] |
pegRatioTTM | -0.934 | 1.500 | -9.56 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0152 | 1.000 | -2.12 | 0 | [0.1 - 0.5] |
Total Score | -1.286 |
Sihuan Pharmaceutical
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in the People's Republic of China. It offers drugs in the oncology, metabolic diseases, digestive system, and other therapeutic areas. The company is also involved in the investment and sale of medical beauty products; manufacture of medical instruments; investment in properties; construction for medical projects; and project preparation for pharmaceutical products manufacturing. In addition, it provides information support, general hospital, hospital management, biotechnology promotion, and medical aesthetic research and development services. The company was founded in 2001 and is based in Wanchai, Hong Kong.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.